Preferred Label : eptinezumab;

MeSH hyponym : ALD-403;

UNII : 8202AY8I7H;

Details


Main resources

You can consult :


https://www.omedit-centre.fr/medias/Eptinezumab-Vyepti_Perfusion-IV-en-HAD.pdf
2025
France
scientific and technical information
hospital admission, nos
vyepti
eptinezumab
perfusion
eptinezumab
home care services, hospital-based
perfusion, nos

---
https://www.has-sante.fr/jcms/p_3382726/fr/vyepti-eptinezumab
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
eptinezumab
migraine disorders
infusions, intravenous
chronic disease
Chronic Migraine
vyepti
Refractory migraine (disorder)
evaluation of the transparency committee
eptinezumab

---
https://www.cadth.ca/fr/eptinezumab
2022
false
false
false
Canada
French
English
eptinezumab
migraine disorders
adult
drug evaluation
eptinezumab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/vyepti
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
eptinezumab
eptinezumab
migraine disorders
eptinezumab
adult
drug approval
europe
chronic disease
Chronic Migraine
aged
infusions, intravenous
Product containing only eptinezumab in parenteral dose form (medicinal product form)
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
calcitonin gene-related peptide
drug evaluation, preclinical
Refractory migraine (disorder)

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.